Cord blood and platelet plasma for dry macular degeneration
Part of Eyes & vision clinical trials.
This trial tests if a treatment made from umbilical cord blood and platelet-rich plasma can help people with dry age-related macular degeneration. The treatment is given as an injection into the eye, and the goal is to see if it slows vision loss or improves sight.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 65 years old or older.
- You have dry (non-wet) age-related macular degeneration in both eyes.
- Your vision in the study eye is between 1/10 and 4/10 on a standard eye chart (roughly able to read large print but not fine print).
- You do not have other eye diseases like glaucoma or lazy eye, or health problems like diabetes that could affect the results.
- You have not had previous injections inside the eye for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether injections made from umbilical cord blood “platelet-rich plasma” can improve vision in people with dry age-related macular degeneration (AMD) in both eyes. It targets older adults with specific vision levels and no major other eye or medical problems that could affect the results.
This early-stage study tests whether a stem-cell–derived transplant to the back of the eye is safe and tolerable in people with dry age-related macular degeneration (AMD). If you qualify, you may receive the transplant and have close follow-up to watch for side effects.
This trial tests a patch of retinal cells implanted under the retina to see if it can slow or stop vision loss from advanced dry AMD (geographic atrophy). It may help people whose central vision is already affected.
This early-phase study tests whether transplanting lab-made retinal cells from your own body can slow vision loss from geographic atrophy caused by dry age-related macular degeneration. It involves eye surgery and frequent follow-up to check safety and early signs of benefit.
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
This trial tests if transplanting lab-grown retinal cells (RPE cells) into the eye can help people with late-stage dry AMD. It aims to slow vision loss and possibly improve sight.
Hear when a new Dry Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.